Abstract: Objective To investigate the effect of humanized CDR3δ1-grafted antibody GTM-Fc on PBMC-mediated treatment of human hepatoma. Methods HepG2.2.15 were transplanted by subcutaneous injection to form transplantation tumor in nude mice. Then were divided into PBS group, PBMC group and PBMC+Ab group, nine mice in each group. Mice in PBS group were injected within tumor with 100μL PBS(phosphate buffer solution) while those in PBMC group and PBMC+Ab group were injected respectively with 1×106 of PBMC and 1×106 of PBMC added 3ug GTM-Fc. Repeated the treatment every three days and measured the weight and the tumor size. executed all the mice three day after the fith treatment. Flow cytometry(FCM) was performed to detect the binding capability of GTM-Fc to human hepatic carcinoma cells(HHCC). The antibody-dependent cell-mediated cytotoxicity (ADCC) was applied to detect the effect of GTM-Fc on PBMC-mediated killing HHCC in vivo and in vitro. Results Humanized CDR3δ1-grafted antibody GTM-Fc displayed excellent binding activity to HHCC. Experiments in vitro showed that GTM-Fc augmented the killing effect of PBMC to HHCC. Conclusions Humanized CDR3δ1-grafted antibody GTM-Fc can enhance the killing effect of PBMC on HHCC.

Key words: humanized antibody, GTM-Fc, PBMC